This one does look a little iffy. Their web page doesn't seem to work (I couldn't get beyond the home page). Middling PII results published a good while ago:
>>Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.
Prostate 1999 Apr 1;39(1):54-9 (ISSN: 0270-4137)
Murphy GP; Tjoa BA; Simmons SJ; Ragde H; Rogers M; Elgamal A; Kenny GM; Troychak MJ; Salgaller ML; Boynton AL [Find other articles with these Authors]
Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, Washington 98125, USA.
BACKGROUND: A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects admitted with presumed local recurrence of prostate cancer after primary treatment failure. METHODS: All subjects received six infusions of DC pulsed with PSM-P1 and -P2 at 6-week intervals. Clinical monitoring was conducted pre-, during, and post-phase II study. Data included: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint scan, and chest X-ray, as well as other assays to monitor cellular and humoral immune responses. RESULTS: One complete and 10 partial responders were identified from this group based on National Prostate Cancer Project criteria, or on a 50% reduction of prostate-specific antigen (PSA), or on a significant resolution in lesions (biopsy-proven when possible) on ProstaScint scan. CONCLUSIONS: About 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggests that DC-based cancer vaccines may provide an alternative therapy for prostate cancer patients whose primary treatment failed.<<
snip
The latest S-1/A has less info than that, and all I can find since the above is one article on the monitoring procedure used in the trials (immunocompetence being pushed as a good measure), and a bunch of self-serving review articles. The PIII protocol has been submitted, but a search hasn't yet turned up an approved one online. As Rick once said of INCR (trading below $2): "flying right along -- not!"
Sooo, shall we look at the graph of SGEN and short this sucker right away?
siliconinvestor.com
Cheers, Tuck |
